Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Kefford

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
International Journal of Oncology|May 11, 2011
A novel model for metastasis suppression involving regulation of nuclear precursor messenger-RNA stabilityB Henderson, D McDonald, S Jones, et al.
British Journal of Cancer|December 9, 2010
Targeting BRAF for patients with melanomaH-T Arkenau, R Kefford, G V Long
Australian Family Physician|March 21, 1998
Cancer in the family. Part 2R Kefford, K Tucker, M Friedlander, et al.
Australian and New Zealand Journal of Medicine|July 23, 1998
Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicinH Gurney, P Harnett, R Kefford, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 1995
Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancerH Gurney, P Harnett, R Stuart-Harris, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Epirubicin: a phase II study in recurrent small-cell lung cancerM Rosenthal, R Kefford, D Raghavan, et al.
Cancer|October 1, 1989
Bone metastases in hypernephroma. Frequency of scapular involvementH Gurney, G Larcos, M McKay, et al.
The Medical Journal of Australia|March 6, 1989
Health-care interpreters and cancerD Gorman, R Stuart-Harris, A O Langlands, et al.
The British Journal of Dermatology|July 22, 2014
Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeksR Anforth, G Carlos, A Clements, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 1985
Sequence and evolution of the human T-cell antigen receptor beta-chain genesA Tunnacliffe, R Kefford, C Milstein, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
International Journal of Oncology|May 11, 2011
A novel model for metastasis suppression involving regulation of nuclear precursor messenger-RNA stabilityB Henderson, D McDonald, S Jones, et al.
British Journal of Cancer|December 9, 2010
Targeting BRAF for patients with melanomaH-T Arkenau, R Kefford, G V Long
Australian Family Physician|March 21, 1998
Cancer in the family. Part 2R Kefford, K Tucker, M Friedlander, et al.
Australian and New Zealand Journal of Medicine|July 23, 1998
Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicinH Gurney, P Harnett, R Kefford, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 1995
Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancerH Gurney, P Harnett, R Stuart-Harris, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Epirubicin: a phase II study in recurrent small-cell lung cancerM Rosenthal, R Kefford, D Raghavan, et al.
Cancer|October 1, 1989
Bone metastases in hypernephroma. Frequency of scapular involvementH Gurney, G Larcos, M McKay, et al.
The Medical Journal of Australia|March 6, 1989
Health-care interpreters and cancerD Gorman, R Stuart-Harris, A O Langlands, et al.
The British Journal of Dermatology|July 22, 2014
Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeksR Anforth, G Carlos, A Clements, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 1985
Sequence and evolution of the human T-cell antigen receptor beta-chain genesA Tunnacliffe, R Kefford, C Milstein, et al.
Pageof 4